Print Page  |  Close Window

Press Releases

June 04, 2018Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018

CRANBURY, N.J., June 04, 2018 (GLOBE NEWSWIRE) -- Stelis Biopharma and Oncobiologics, Inc. (NASDAQ:ONS) today announced that they will unveil a new contract development and manufacturing (“CDMO”) effort at BIO 2018 in Boston.  Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma will offer development stage biotech companies access to a suite of CDMO services. Oncobiologics will utilize its proprietary BioSymphony™ platform to offer mammalian cell process development and bulk drug manufacturing, while Stelis will offer microbial development and manufacturing capabilities as well as fill-finish services, including drug formulation development and lyophilization for biological products.

Joe Thomas, Chief Executive Officer of Stelis Biopharma and member of the Oncobiologics Board of Directors, stated, “We are excited to launch this collaboration at BIO 2018.  We believe this CDMO concept offers development stage biotech companies an exciting ‘DNA to clinic’ option for preparing their biologic products for clinical trials and commercial launch.  They can access technical excellence, rapid development and attractive economics not found with other CDMO business models.”

“We are pleased to leverage our BioSymphony platform capacity with development stage partners.  Our CDMO offering has already generated great interest and we look forward to meeting with additional prospective partners at BIO to further educate them on our innovative services model," commented Pankaj Mohan, Ph.D., Chairman and CEO of Oncobiologics.

The Bio2Source initiative is facilitated by GMS Tenshi, a significant strategic investor both in Stelis Biopharma and Oncobiologics Inc.  GMS Tenshi, based in Singapore is a joint-venture between Tenshi Life Sciences Private Limited, an India based life sciences company and GMS Holdings, a Jordan based group with diversified assets across the pharmaceutical and biopharmaceutical space.

The Bio2Source team, including representatives from Oncobiologics and Stelis will be available at the Stelis booth (Booth 511 in the Contract Services Zone) during the BIO 2018 conference (June 4 – 7, 2018).

About Oncobiologics, Inc. and its BioSymphony™ Platform
Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) therapeutics. Oncobiologics is advancing a pipeline of innovative and biosimilar product candidates, three of which are currently in, or about to enter, clinical development. By leveraging its proprietary BioSymphony™ Platform, Oncobiologics is able to produce high-quality innovative and biosimilar mAb candidates efficiently and cost-effectively. The BioSymphony engine is particularly suitable for developing technically challenging and commercially attractive mAbs to meet the need for clinically important yet affordable drugs. The BioSymphony Platform is used for both in-house programs as well as engaging capacity to provide external CDMO services. Led by a team of biopharmaceutical experts, Oncobiologics operates from a state-of-the-art fully integrated research, development, and manufacturing facility in Cranbury, New Jersey. For more information, please visit www.oncobiologics.com.

About Stelis Biopharma
Stelis Biopharma Private Limited (Stelis), headquartered in Bengaluru, India, is a vertically integrated biopharmaceutical company with R&D, process scale-up and end-to-end manufacturing capabilities from biological drug substance to aseptic fill-finish in various injectable formats. Stelis is committed to high-quality, affordable bio-therapeutics play through a combination of its internal biosimilars pipeline and high-end CDMO and CMO services for external customers. Stelis houses two facilities in Bengaluru India including a state-of-the-art R&D and clinical-scale GMP facility and a 200,000 square feet bio-manufacturing campus for commercial manufacturing of recombinant bio-therapeutics from drug substance to finished & packed product. All facilities are designed to conform to global regulatory standards and follow cGMP guidelines. Stelis, with its well-resourced infrastructure, biosimilar development oriented skill set, and group's rich heritage in complex manufacturing is poised to become one of the most preferred partners for development and manufacture of biotherapeutics.

CONTACTS:
Oncobiologics:             
Lawrence A. Kenyon
Chief Financial Officer
LawrenceKenyon@oncobiologics.com 

Media & Investors:       
Jeremy Feffer
Managing Director
LifeSci Advisors, LLC
T: 212.915.2568 
jeremy@lifesciadvisors.com 

Primary Logo

Oncobiologics, Inc.